The US Food and Drug Administration has approved GlaxoSmithKline’s Lamictal XR (lamotrigine) extended-release tablets as a once-a-day therapy for epilepsy patients suffering from partial onset seizures.
Lamictal XR has been approved as an add-on therapy for adult and adolescent patients who experience partial seizures with or without secondary generalisation.
Go deeper with GlobalData
GlaxoSmithKline chairman Dean Naritoku said that many patients required multiple doses of one or more medications to control their epilepsy.
“This made taking their medicines even more challenging. Lamictal XR is a once-daily advance for patients with epilepsy who still experience seizures while taking their current therapy,” said Naritokou.
Lamictal XR reduced the frequency of partial seizures during a 19-week study.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
